In the music industry, there wasn’t many up-and-coming stars who could match the meteoric rise Selena Gomez had been experiencing for several years. Then, starting in 2015, it appeared as though she had decided to slow down. Countless news outlets, being what they are, immediately started up the rumour mill and began to speculate about what it was exactly that had befallen Selena Gomez. Lupus, to their surprise, turned out to be the answer.
It was not drug abuse or some other condition of that nature which provides such fertile ground for rumours and celebrity gossip. Instead, it was a very serious disease, one that the general public may not know enough about. As such, it certainly warrants a closer look.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs
Founded first in Basel, Switzerland in 1999 and led by an experienced management team, ImmuPharma now has important R&D collaboration arrangements with highly respected health and medical research laboratories in Europe. The company plans either to bring its drug candidates to market itself, or to license them in corporate deals to other pharmaceutical companies.
